Pathophysiology of coronary microvascular dysfunction
Vascul Pharmacol. 2023 Oct 26:107239. doi: 10.1016/j.vph.2023.107239. Online ahead of print.ABSTRACTThe term "coronary microvascular dysfunction" (CMD) encompasses several pathogenetic mechanisms resulting in functional and/or structural changes in the coronary microcirculation. CMD often determines angina and myocardial ischemia in a broad spectrum of cardiovascular diseases, including patients with ischemia with non-obstructive coronary arteries or ischemia with obstructive coronary artery disease, infarction with non-obstructive coronary arteries, cardiomyopathies, the Takotsubo syndrome and heart failure, especially he...
Source: Vascular Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Filippo Crea Rocco A Montone Source Type: research
Review of plaque characteristics in individuals with sudden coronary death
Vascul Pharmacol. 2023 Oct 26:107240. doi: 10.1016/j.vph.2023.107240. Online ahead of print.ABSTRACTCoronary artery disease (CAD) remains the leading cause of death in the Western world in individuals >20 years of age. CAD is the most common substrate underlying sudden cardiac death (SCD) in the Western world, being responsible for 50-75% of SCDs. In individuals dying suddenly with coronary thrombosis, plaque rupture occurs in 65%, plaque erosion in 30% and calcified nodule in 5%. We evaluated the extent of calcification in radiographs of hearts from patients dying of SCD and showed that calcification is absent in nearl...
Source: Vascular Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Takao Konishi Renu Virmani Hiroyuki J Innouchi Kenji Kawai Teruo Sekimoto Rika Kawakami Aloke V Finn Source Type: research
Pathophysiology of coronary microvascular dysfunction
Vascul Pharmacol. 2023 Oct 26:107239. doi: 10.1016/j.vph.2023.107239. Online ahead of print.ABSTRACTThe term "coronary microvascular dysfunction" (CMD) encompasses several pathogenetic mechanisms resulting in functional and/or structural changes in the coronary microcirculation. CMD often determines angina and myocardial ischemia in a broad spectrum of cardiovascular diseases, including patients with ischemia with non-obstructive coronary arteries or ischemia with obstructive coronary artery disease, infarction with non-obstructive coronary arteries, cardiomyopathies, the Takotsubo syndrome and heart failure, especially he...
Source: Vascular Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Filippo Crea Rocco A Montone Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21;153:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21;153:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Dru...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Dru...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Dru...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Animal experimental models of ischemic limbs - A systematic review
CONCLUSIONS: This review shows that mice are among the most commonly used animals in limb ischemia research. Simple ligation and excision of the femoral artery is the most common method of creating an ischemic limb; nevertheless, it can result in acute rather than chronic ischemia. A two-stage sequential approach and methods using ameroid constrictors or endovascular blinded stent grafts are more suitable for creating a gradual arterial occlusion typically seen in humans. Selecting the right mouse strain or animal with artificially produced diabetes or hyperlipidaemia is crucial in chronic ischemic limb research. Moreover,...
Source: Vascular Pharmacology - October 6, 2023 Category: Drugs & Pharmacology Authors: Veronika Lovasova Robert Bem Jaroslav Chlupac Michal Dubsky Jitka Husakova Andrea Nemcova Jiri Fronek Source Type: research
Animal experimental models of ischemic limbs - A systematic review
CONCLUSIONS: This review shows that mice are among the most commonly used animals in limb ischemia research. Simple ligation and excision of the femoral artery is the most common method of creating an ischemic limb; nevertheless, it can result in acute rather than chronic ischemia. A two-stage sequential approach and methods using ameroid constrictors or endovascular blinded stent grafts are more suitable for creating a gradual arterial occlusion typically seen in humans. Selecting the right mouse strain or animal with artificially produced diabetes or hyperlipidaemia is crucial in chronic ischemic limb research. Moreover,...
Source: Vascular Pharmacology - October 6, 2023 Category: Drugs & Pharmacology Authors: Veronika Lovasova Robert Bem Jaroslav Chlupac Michal Dubsky Jitka Husakova Andrea Nemcova Jiri Fronek Source Type: research
Animal experimental models of ischemic limbs - A systematic review
CONCLUSIONS: This review shows that mice are among the most commonly used animals in limb ischemia research. Simple ligation and excision of the femoral artery is the most common method of creating an ischemic limb; nevertheless, it can result in acute rather than chronic ischemia. A two-stage sequential approach and methods using ameroid constrictors or endovascular blinded stent grafts are more suitable for creating a gradual arterial occlusion typically seen in humans. Selecting the right mouse strain or animal with artificially produced diabetes or hyperlipidaemia is crucial in chronic ischemic limb research. Moreover,...
Source: Vascular Pharmacology - October 6, 2023 Category: Drugs & Pharmacology Authors: Veronika Lovasova Robert Bem Jaroslav Chlupac Michal Dubsky Jitka Husakova Andrea Nemcova Jiri Fronek Source Type: research
Animal experimental models of ischemic limbs - A systematic review
CONCLUSIONS: This review shows that mice are among the most commonly used animals in limb ischemia research. Simple ligation and excision of the femoral artery is the most common method of creating an ischemic limb; nevertheless, it can result in acute rather than chronic ischemia. A two-stage sequential approach and methods using ameroid constrictors or endovascular blinded stent grafts are more suitable for creating a gradual arterial occlusion typically seen in humans. Selecting the right mouse strain or animal with artificially produced diabetes or hyperlipidaemia is crucial in chronic ischemic limb research. Moreover,...
Source: Vascular Pharmacology - October 6, 2023 Category: Drugs & Pharmacology Authors: Veronika Lovasova Robert Bem Jaroslav Chlupac Michal Dubsky Jitka Husakova Andrea Nemcova Jiri Fronek Source Type: research
Animal experimental models of ischemic limbs - A systematic review
CONCLUSIONS: This review shows that mice are among the most commonly used animals in limb ischemia research. Simple ligation and excision of the femoral artery is the most common method of creating an ischemic limb; nevertheless, it can result in acute rather than chronic ischemia. A two-stage sequential approach and methods using ameroid constrictors or endovascular blinded stent grafts are more suitable for creating a gradual arterial occlusion typically seen in humans. Selecting the right mouse strain or animal with artificially produced diabetes or hyperlipidaemia is crucial in chronic ischemic limb research. Moreover,...
Source: Vascular Pharmacology - October 6, 2023 Category: Drugs & Pharmacology Authors: Veronika Lovasova Robert Bem Jaroslav Chlupac Michal Dubsky Jitka Husakova Andrea Nemcova Jiri Fronek Source Type: research
Animal experimental models of ischemic limbs - A systematic review
CONCLUSIONS: This review shows that mice are among the most commonly used animals in limb ischemia research. Simple ligation and excision of the femoral artery is the most common method of creating an ischemic limb; nevertheless, it can result in acute rather than chronic ischemia. A two-stage sequential approach and methods using ameroid constrictors or endovascular blinded stent grafts are more suitable for creating a gradual arterial occlusion typically seen in humans. Selecting the right mouse strain or animal with artificially produced diabetes or hyperlipidaemia is crucial in chronic ischemic limb research. Moreover,...
Source: Vascular Pharmacology - October 6, 2023 Category: Drugs & Pharmacology Authors: Veronika Lovasova Robert Bem Jaroslav Chlupac Michal Dubsky Jitka Husakova Andrea Nemcova Jiri Fronek Source Type: research
Animal experimental models of ischemic limbs - A systematic review
CONCLUSIONS: This review shows that mice are among the most commonly used animals in limb ischemia research. Simple ligation and excision of the femoral artery is the most common method of creating an ischemic limb; nevertheless, it can result in acute rather than chronic ischemia. A two-stage sequential approach and methods using ameroid constrictors or endovascular blinded stent grafts are more suitable for creating a gradual arterial occlusion typically seen in humans. Selecting the right mouse strain or animal with artificially produced diabetes or hyperlipidaemia is crucial in chronic ischemic limb research. Moreover,...
Source: Vascular Pharmacology - October 6, 2023 Category: Drugs & Pharmacology Authors: Veronika Lovasova Robert Bem Jaroslav Chlupac Michal Dubsky Jitka Husakova Andrea Nemcova Jiri Fronek Source Type: research
